Fludarabine: a new agent with major activity against chronic lymphocytic leukemia

MJ Keating(The University of Texas MD Anderson Cancer Center), KB McCredie(The University of Texas MD Anderson Cancer Center), Barthel Barlogie(The University of Texas MD Anderson Cancer Center), Charles Koller(The University of Texas MD Anderson Cancer Center), J R Redman(The University of Texas MD Anderson Cancer Center), William S. Velasquez(The University of Texas MD Anderson Cancer Center), EJ Freireich(The University of Texas MD Anderson Cancer Center), Moshe Talpaz(University of Michigan), H. Kantarjian(The University of Texas MD Anderson Cancer Center), William Plunkett(The University of Texas MD Anderson Cancer Center)
Blood
July 1, 1989
10.1182/blood.v74.1.19.19
Cited by 456

Related Papers

Activating ESR1 mutations in hormone-resistant metastatic breast cancer
|Nature Genetics|2013|1.2k
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
|Blood|1997|1.2k
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2005|951
Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing
|Nature Genetics|2013|818
Identification of Targetable FGFR Gene Fusions in Diverse Cancers
|Cancer Discovery|2013|737